These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30633927)

  • 1. GATA6: a new predictor for prognosis in ovarian cancer.
    Shen W; Niu N; Lawson B; Qi L; Zhang J; Li T; Zhang H; Liu J
    Hum Pathol; 2019 Apr; 86():163-169. PubMed ID: 30633927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
    Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
    Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types.
    Wang H; Rosen DG; Wang H; Fuller GN; Zhang W; Liu J
    Mod Pathol; 2006 Sep; 19(9):1149-56. PubMed ID: 16729015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CD44 receptor is a molecular predictor of survival in ovarian cancer.
    Rodríguez-Rodríguez L; Sancho-Torres I; Mesonero C; Gibbon DG; Shih WJ; Zotalis G
    Med Oncol; 2003; 20(3):255-63. PubMed ID: 14514975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
    Skírnisdóttir I; Seidal T; Sorbe B
    Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up.
    Geisler JP; Tammela JE; Manahan KJ; Geisler HE; Miller GA; Zhou Z; Wiemann MC
    Eur J Gynaecol Oncol; 2004; 25(2):165-8. PubMed ID: 15032273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic analysis of ovarian cancer associated with endometriosis.
    Kumar S; Munkarah A; Arabi H; Bandyopadhyay S; Semaan A; Hayek K; Garg G; Morris R; Ali-Fehmi R
    Am J Obstet Gynecol; 2011 Jan; 204(1):63.e1-7. PubMed ID: 21074136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
    El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA
    Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma.
    Borgoño CA; Fracchioli S; Yousef GM; Rigault de la Longrais IA; Luo LY; Soosaipillai A; Puopolo M; Grass L; Scorilas A; Diamandis EP; Katsaros D
    Int J Cancer; 2003 Sep; 106(4):605-610. PubMed ID: 12845660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
    Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
    Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.
    Rambau PF; Vierkant RA; Intermaggio MP; Kelemen LE; Goodman MT; Herpel E; Pharoah PD; Kommoss S; Jimenez-Linan M; Karlan BY; Gentry-Maharaj A; Menon U; Polo SH; Candido Dos Reis FJ; Doherty JA; Gayther SA; Sharma R; Larson MC; Harnett PR; Hatfield E; de Andrade JM; Nelson GS; Steed H; Schildkraut JM; Carney ME; Høgdall E; Whittemore AS; Widschwendter M; Kennedy CJ; Wang F; Wang Q; Wang C; Armasu SM; Daley F; Coulson P; Jones ME; Anglesio MS; Chow C; de Fazio A; García-Closas M; Brucker SY; Cybulski C; Harris HR; Hartkopf AD; Huzarski T; Jensen A; Lubiński J; Oszurek O; Benitez J; Mina F; Staebler A; Taran FA; Pasternak J; Talhouk A; Rossing MA; Hendley J; ; Edwards RP; Fereday S; Modugno F; Ness RB; Sieh W; El-Bahrawy MA; Winham SJ; Lester J; Kjaer SK; Gronwald J; Sinn P; Fasching PA; Chang-Claude J; Moysich KB; Bowtell DD; Hernandez BY; Luk H; Behrens S; Shah M; Jung A; Ghatage P; Alsop J; Alsop K; García-Donas J; Thompson PJ; Swerdlow AJ; Karpinskyj C; Cazorla-Jiménez A; García MJ; Deen S; Wilkens LR; Palacios J; Berchuck A; Koziak JM; Brenton JD; Cook LS; Goode EL; Huntsman DG; Ramus SJ; Köbel M
    J Pathol Clin Res; 2018 Oct; 4(4):250-261. PubMed ID: 30062862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome in serous ovarian cancer is not associated with LATS expression.
    Montavon C; Stricker GR; Schoetzau A; Heinzelmann-Schwarz V; Jacob F; Fedier A
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2737-2749. PubMed ID: 31586262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-H4 overexpression in ovarian tumors.
    Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
    Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients.
    Mizuno M; Kajiyama H; Shibata K; Mizuno K; Kawai M; Nagasaka T; Kikkawa F
    Br J Cancer; 2015 Apr; 112(8):1376-83. PubMed ID: 25867257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
    Borgoño CA; Kishi T; Scorilas A; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
    Clin Cancer Res; 2006 Mar; 12(5):1487-93. PubMed ID: 16533772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor (VEGF) and cyclooxygenase 2 (COX 2) immunostaining in ovarian cancer.
    Whynott RM; Manahan P; Geisler JP
    Eur J Gynaecol Oncol; 2016; 37(2):164-6. PubMed ID: 27172738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma.
    Fujimura M; Hidaka T; Kataoka K; Yamakawa Y; Akada S; Teranishi A; Saito S
    Am J Surg Pathol; 2001 May; 25(5):667-72. PubMed ID: 11342781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and correlation of Lewis y antigen and integrins α5 and β1 in ovarian serous and mucinous carcinoma.
    Li Q; Liu S; Lin B; Yan L; Wang Y; Wang C; Zhang S
    Int J Gynecol Cancer; 2010 Dec; 20(9):1482-9. PubMed ID: 21119363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.